• Kim YH, Kong SY, Lee MR, Woo SM, Han SS, Park SJ, Lee WJ, Lee DE, Kim MK, Choi SI, Choi WY, Yoon KA, Jeon JW. Application of plasma circulating KRAS mutations as a predictive biomarker for targeted treatment of pancreatic cancer. Cancer Science. 2024;115(4):1283-1295. (IF: 5.7)
• Kong SY, Woo SM, Kim MK, Park BR, Kim YH, Choi WY, Han SS, Lee WJ, Park SJ. Genomic instability of circulating tumor DNA as a prognostic marker for pancreatic cancer survival: a prospective cohort study. Cancers. 2021;13(21):5466-. (IF: 6.639)
• Kong SY, Shim HE, Kwon MJ, Park IH, Kim MK, Shim SH, Lee GS, Kim YH, Kim SK, Lee ES. Targeted next generation sequencing of circulating tumor DNA provides prognostic information for management in breast cancer patients. Annals of Translational Medicine. 2022;10(2):28-. (IF: 3.616)
• Kong SY, Yoo JS, Lee HY, Cho EH, Yoon KA, Kim MK, Joo JN, Lee ES, Kang HS, Lee SY, Lee DO, Lim MC. Exon splicing analysis of intronic variants in multigene cancer panel testing for hereditary breast/ovarian cancer. Cancer Science. 2020;111(10):3912-3925. (IF: 4.966)
• Kim YH, Woo SM, Jeon AR, Choi SI, Park SJ, Hong EK, Lee YS, Lim JE, Ko JW, Kim MK, Kong SY, Lee WJ, Han SS, Ko YH, Lee JH. Development of patient-derived preclinical platform for metastatic pancreatic cancer: PDOX and a subsequent organoid model system using percutaneous biopsy samples. Frontiers in Oncology. 2019;9:875-. (IF: 4.137)
• Park SR, Ryu BY, Kong SY, Oh CR, Lim HS, Kim MK. Genome-wide copy number alteration and VEGFA amplification of circulating cell-free DNA as a biomarker in advanced hepatocellular carcinoma patients treated with sorafenib. BMC Cancer. 2019;19(1):292-. (IF: 2.933)
• Kong SY, Lee ES, Park CY, Yoon KA, Kim JH, Park IH, Park SJ, Kim MK, Jang WY, Cho SY, Park BR. Integrative molecular profiling identifies a novel cluster of estrogen receptor-positive breast cancer in very young women. Cancer Science. 2019;110(5):1760-1770. (IF: 4.751)
• Kong SY, Lee GS, Yoo JS, Shim SH, Park IH, Lee EK, Lee ES, Kim YH, Kwon YM. Integrative in vivo drug testing using gene expression signature and patient-derived xenografts from treatment-refractory HER2 positive and triple-negative subtypes of breast cancer. Cancers. 2019;11(4):E574. (IF: 6.162)
• Park IH, Yang HN, Jeon SY, Hwang JA, Kim MK, Kong SY, Shim SH, Lee GS. Anti-tumor activity of BET inhibitors in androgen-receptor-expressing triple-negative breast cancer. Scientific Reports. 2019;9(1):13305-. (IF: 4.122)
• Kong SY, Kim TH, Lee WJ, Woo SM, Kim MK, Joo JN, Yoon KA, Park BR, Park SJ, Han SS, Lee JH, Hong EK, Kim YH, Moon H. Induction chemotherapy with gemcitabine and cisplatin followed by simultaneous integrated boost-intensity modulated radiotherapy with concurrent gemcitabine for locally advanced unresectable pancreatic cancer: results from a feasibility study. Cancer Research and Treatment. 2017;49(4):1022-1032. (IF: 3.772)
• Kong SY, Yoon KA, Kim MK, Eom HS, Lee HW, Park WS, Son JY, Kim MJ. Adverse prognostic impact of vascular endothelial growth factor gene polymorphisms in patients with diffuse large B-cell lymphoma. Leukemia & Lymphoma. 2017. (IF: 2.755)
• Kong SY, Kim MK, Yoon KA, Park EY, Joo JN, Lee EY, Eom HS. Interleukin-10 polymorphisms in association with prognosis in patients with B-cell lymphoma treated by R-CHOP. Genomics & Informatics. 2016;14:205-210.
• Park KS, Kong SY, Kim MK, Lee KH, Kim KS, Kim JW, Lee JY, Oh N, Park JH, Hae SH. The ELK3-GATA3 axis orchestrates invasion and metastasis of breast cancer cells in vitro and in vivo. Oncotarget. 2016;7(40):65137-65146. (IF: 5.008)